A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this early-stage clinical study is to demonstrate an effect of
single doses of CK-2017357 on measures of skeletal muscle function and fatigability in
patients with peripheral artery disease and symptomatic claudication.